



1631\$

Dkt. 0575/50950/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wayne A. Hendrickson et al.  
U.S. Serial No. : 09/609,027  
Filed : June 29, 2000  
For : CONJUGATED LIGANDS FOR THE STIMULATION OF  
BLOOD CELL PROLIFERATION BY EFFECTING  
DIMERIZATION OF THE RECEPTOR FOR STEM  
CELL FACTOR

RECEIVED

OCT 11 2001

TECH CENTER 1600/2900

1185 Avenue of the Americas  
New York, New York 10036  
October 2, 2001

#111B  
Plunkett  
10/12/01

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

AMENDMENT IN RESPONSE TO AUGUST 2, 2001 OFFICE COMMUNICATION AND  
PETITION FOR ONE MONTH EXTENSION OF TIME

This amendment is submitted in response to an August 2, 2001 Communication issued in connection with the above-identified application. A response to the August 2, 2001 Communication was due September 2, 2001. Applicants hereby petition for a one-month extension of time from September 2, 2001 to October 2, 2001. The fee for a one-month extension of time for a large entity is ONE HUNDRED AND TEN DOLLARS (\$110.00) and a check for this amount is enclosed. With a one-month extension of time, a response to the August 2, 2001 Communication is now due October 2, 2001. Accordingly, this response is being timely filed.

Applicants request that the following amendments be made to the above-identified application:

10/10/2001 JBALINAN 00000012 09609027

01 FC:115

110.00 DP

**In the Written Description:**

Please replace the figure description starting at page 12, line 20 with the following rewritten figure description:

---

81  
--Figure 3.

Structure-based sequence alignment of SCF (SEQ ID NO:1) with other short-chain helical cytokines of human species. The dots denote gaps. M-CSF (SEQ ID NO:2), IL-4 (SEQ ID NO:3), GM-CSF (SEQ ID NO:4), IL-2 (SEQ ID NO:5) and IL-5 (SEQ ID NO:6) were aligned with SCF structure through structural superposition using TOSS (Hendrickson, 1979) and O (Jones et al., 1991). C $\alpha$  atoms were included if within 3.0 Å of their counterparts after superposition and at least three consecutive such residues are found in the fragment. The secondary structure elements were assigned according to the output of the PROCHECK program (Laskowski et al., 1993) except the helix assignment for residues 35-38, which was identified by inspection of the hydrogen-bond pattern. Secondary structures are shown shaded with filled boxes referring to  $\alpha$ -helices, half-filled boxes to  $3_{10}$ -helices and arrows to  $\beta$ -strands. The solvent accessibility of the SCF dimer is indicated for each

B1 residue by an open circle if the fractional solvent accessibility is >0.4, a half-filled circle if it is 0.1-0.4, and a filled circle if it is <0.1. Residues at the SCF dimer interface are identified by stars, and the N-linked glycosylation sites by Ys above the Asn residues.--

---

Please replace the Figure description starting at page 14, line 5 with the following rewritten Figure description:

---

B2 --Figure 5.

Sequence alignment of SCF from human (SEQ ID NO:7), mouse (SEQ ID NO:8), rat (SEQ ID NO:9) and dog (SEQ ID NO:10). (Anderson et al., 1990; Huang et al., 1990; Martin et al. 1990; Shull et al., 1992). The residues that are conserved in human and dog but different from rat and mouse are shadowed. Five regions of divergent sequence are identified (Roman numerals). Dots denote gaps, and dashes indicate residues identical to the human residues.--

---

Please replace the paragraph beginning at page 62, line 3 with the following rewritten paragraph.

---

B3 --Although SCF has the characteristic features of short-chain helical cytokines, as among other members, both sequence and structure are highly divergent. If anything,